Full text is available at the source.
Abstract
Viusid is being evaluated for its potential to improve symptoms in patients with Long COVID syndrome.
- Long COVID syndrome is identified by ongoing neurological, respiratory, and systemic symptoms after SARS-CoV-2 infection.
- Current treatment options for Long COVID syndrome are limited and not widely effective.
- Viusid is an oral formulation designed to act as an antioxidant and help modulate the immune response.
- The study aims to assess the effectiveness of Viusid specifically for chronic inflammatory symptoms associated with Long COVID syndrome.
Simplified